Isaac Quiros-Fernandez

Mr. Isaac Quiros-Fernandez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Uniciencia
Verified
Journal Article
Open access
PDF file
Jose Arturo Arturo MoraJose Arturo Arturo Mora
Jose Arturo Arturo Mora
SMSusana Mesén-Porras
Susana Mesén-Porras
IQIsaac Quiros-Fernandez
Isaac Quiros-Fernandez
MKMariana Kop-Montero
Mariana Kop-Montero
ARAndrea Rojas-Cespedes
Andrea Rojas-Cespedes
RMRodrigo Mora
Rodrigo Mora
Cancer is a complex genetic disease with reduced treatment alternatives due to tumor heterogeneity and drug multiresistance emergence. The sphingolipid (SL) metabolic pathway integrates different responses of cellular stress signals and defines cell survival. Therefore, we suggest studying the perturbations on the sphingolipid pathway (SLP) caused by chemotherapeutic drugs using a systems biology approach to evaluate its functionality as a drug response sensor. We used a sphingomyelin-BODIPY (SM-BOD) sensor to study SL metabolism by flow cytometry and live cell imaging in different cancer models. To decode pathway complexity, we implemented Gussian mixture models, ordinary differential equations models, unsupervised classification algorithms and a fuzzy logic approach to assess its utility as a chemotherapy response sensor. Our results show that chemotherapeutic drugs perturb the SLP in different ways in a cell line-specific manner. In addition, we found that few SM-BOD fluorescence features predict chemosensitivity with high accuracy. Finally, we found that the relative species composition of SL appears to contribute to the resulting cytotoxicity of many treatments. This report offers a conceptual and mathematical framework for developing personalized mathematical models to predict and improve cancer therapy.

18 September 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
IQIsaac Quiros-Fernandez
Isaac Quiros-Fernandez
Lucía Figueroa-ProttiLucía Figueroa-Protti
Lucía Figueroa-Protti
Jorge L. Arias-AriasJorge L. Arias-Arias
Jorge L. Arias-Arias
Norman Brenes-CorderoNorman Brenes-Cordero
Norman Brenes-Cordero
FCFrancisco Siles Canales
Francisco Siles Canales
RMRodrigo Mora
Rodrigo Mora
In the absence of new therapeutic strategies, chemotherapeutic drugs are the most widely used strategy against metastatic breast cancer, in spite of eliciting multiple adverse effects and having low responses with an average 5-year patient survival rate. Among the new therapeutic targets that are currently in clinical trials, here, we addressed the association between the regulation of the metabolic process of autophagy and the exposure of damage-associated molecular patterns associated (DAMPs) to immunogenic cell death (ICD), which has not been previously studied. After validating an mCHR-GFP tandem LC3 sensor capacity to report dynamic changes of the autophagic metabolic flux in response to external stimuli and demonstrating that both basal autophagy levels and response to diverse autophagy regulators fluctuate among different cell lines, we explored the interaction between autophagy modulators and chemotherapeutic agents in regards of cytotoxicity and ICD using three different breast cancer cell lines. Since these interactions are very complex and variable throughout different cell lines, we designed a perturbation-based model in which we propose specific modes of action of chemotherapeutic agents on the autophagic flux and the corresponding strategies of modulation to enhance the response to chemotherapy. Our results point towards a promising therapeutic potential of the metabolic regulation of autophagy to overcome chemotherapy resistance by eliciting ICD.

1 January 2026 in Revista del colegio de microbiólogos y químicos clínicos de Costa Rica
Verified
Journal Article
Closed access
IQIsaac Quiros-Fernandez
Isaac Quiros-Fernandez
Las terapias celulares adoptivas han revolucionado los tratamientos oncológicos al aprovechar la actividad antitumoral de células inmunes autólogas como fármacos vivos contra tumores. Tres estrategias han demostrado ser efectivas en el tratamiento de diversos cánceres, los linfocitos infiltrantes de tumores, las terapias con linfocitos T que expresan TCRs y células CAR-T antitumorales. La evolución tecnológica ha impulsado mejoras en ingeniería genética y en el diseño de receptores CAR de diferentes generaciones, incrementando la persistencia y eficacia antitumoral. Sin embargo, existen limitaciones, atribuibles a la heterogeneidad antigénica y a la inmunosupresión del microambiente tumoral. En paralelo, la manufactura de estas terapias ha avanzado hacia sistemas cerrados que integran la selección, modificación, expansión y formulación celular, reduciendo los requisitos de infraestructura compleja y facilitando la implementación en sistemas de salud en desarrollo. Las terapias celulares adoptivas han pasado de la investigación experimental a convertirse en terapias aprobadas con alto impacto clínico. Su progresiva implementación en sistemas de salud en desarrollo, como el de Costa Rica, plantea un desafío, pero al mismo tiempo un compromiso ineludible con la población costarricense.